Table 3.

Plasma level of CCL11 or expression of CCR3 according to change in visual acuity

	Gain of minimum 10 ETDRS letters (n = 10)	VA change of less than 10 ETDRS letters (n = 56)	Loss of minimum 10 ETDRS letters (n = 16)	P-value Kruskal-Wallis test
CCL11 plasma level Median (IQR)	473.6 (408.9;580.7)	534.1 (323.0;710.6)	427.7 (243.7;762.5)	0.725
CCR3 positive granulocytes Median (IQR)	4.85 (3.18;6.08)	5.50 (4.13;9.67)	7.30 (3.18;10.7)	0.530
	Gain of minimum 15 ETDRS letters (n = 7)	VA change of less than 15 ETDRS letters (n = 64)	Loss of minimum 15 ETDRS letters (n = 11)
CCL11 plasma level Median (IQR)	432,3 (390.5;635.8)	541.2 (351.4;699.5)	349.2 (240.7;667.1)	0.382
CCR3 positive granulocytes Median (IQR)	4.60 (2.65;6.90)	5.50 (4.13;9.67)	8.00 (3.65;10.60)	0.496

The table shows the plasma level of CCL11 and expression of CCR3 among patients with neovascular AMD in active treatment with anti-VEGF. The clinical relevance of CCL11 and CCR3 was tested by dividing the patients in groups according to change in visual acuity (VA). First we tested by dividing the patients in three groups according to a change in VA of minimum 10 ETDRS letters and secondly by dividing the patients in three groups according to a VA change of minimum 15 ETDRS letters. Difference among groups is calculated using Kruskal-Wallis test. P-values are given.

IQR Inter Quartile Range, BMI Body Mass Index, ETDRS Early Treatment Diabetic Retinopathy Study.